Matthew Trotter
Overview
Explore the profile of Matthew Trotter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aguilar B, Gibbs D, Reiss D, McConnell M, Danziger S, Dervan A, et al.
Gigascience
. 2020 Jul;
9(7).
PMID: 32696951
Background: Mechanistic models, when combined with pertinent data, can improve our knowledge regarding important molecular and cellular mechanisms found in cancer. These models make the prediction of tissue-level response to...
2.
Mason M, Schinke C, Eng C, Towfic F, Gruber F, Dervan A, et al.
Leukemia
. 2020 Feb;
34(7):1866-1874.
PMID: 32060406
While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene...
3.
Bolouri H, Young M, Beilke J, Johnson R, Fox B, Huang L, et al.
Sci Rep
. 2020 Feb;
10(1):1915.
PMID: 32024856
Failure to clear antigens causes CD8 T cells to become increasingly hypo-functional, a state known as exhaustion. We combined manually extracted information from published literature with gene expression data from...
4.
Mikulasova A, Ashby C, Tytarenko R, Qu P, Rosenthal A, Dent J, et al.
Haematologica
. 2019 Jun;
105(4):1055-1066.
PMID: 31221783
is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. is important biologically and clinically in multiple myeloma, but the mechanisms underlying its...
5.
Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F, et al.
Leukemia
. 2018 Jul;
33(1):159-170.
PMID: 29967379
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been...
6.
Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F, et al.
Blood
. 2018 Jun;
132(6):587-597.
PMID: 29884741
Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and...
7.
Hagner P, Chiu H, Ortiz M, Apollonio B, Wang M, Couto S, et al.
Br J Haematol
. 2017 Aug;
179(3):399-409.
PMID: 28771673
Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action...
8.
Barandalla M, Shi H, Xiao H, Colleoni S, Galli C, Lio P, et al.
Stem Cell Res Ther
. 2017 Jul;
8(1):160.
PMID: 28676096
Background: Human embryonic stem cells (hESCs) potentially offer new routes to study, on the basis of the Developmental Origins of Health and Disease (DOHaD) concept, how the maternal environment during...
9.
Hagner P, Man H, Fontanillo C, Wang M, Couto S, Breider M, et al.
Blood
. 2015 May;
126(6):779-89.
PMID: 26002965
Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding...
10.
Moyon S, Dubessy A, Aigrot M, Trotter M, Huang J, Dauphinot L, et al.
J Neurosci
. 2015 Jan;
35(1):4-20.
PMID: 25568099
The declining efficiency of myelin regeneration in individuals with multiple sclerosis has stimulated a search for ways by which it might be therapeutically enhanced. Here we have used gene expression...